Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	37.94B
Revenue (ttm)	17.26B +4.3%
Net Income	1.41B
EPS	1.21
Shares Out	1.15B
PE Ratio	27.33
Forward PE	12.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,524,265
Open	33.26
Previous Close	33.21
Day's Range	32.19 - 33.44
52-Week Range	12.47 - 33.44
Beta	0.66
Analysts	Strong Buy
Price Target	34.67 (+4.84%)
Earnings Date	Jan 28, 2026

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 36,830
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Analyst Summary

According to 9 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $34.67, which is an increase of 4.84% from the latest price.

Price Target

$34.67

(4.84% upside)

Analyst Consensus: Strong Buy